Stoke Therapeutics and Biogen have begun dosing in the global Phase III EMPEROR study of zorevunersen for Dravet syndrome, ...

The study will assess the efficacy and safety of zorevunersen compared to sham over a 52-week treatment period.

Stoke Therapeutics Inc (STOK) reports promising advancements in its Dravet syndrome program and strategic partnerships, ...

The global Phase III EMPEROR trial (NCT06872125) will evaluate the safety and efficacy of zorevunersen, a novel antisense ...

Reports Q2 revenue $13.8M, consensus $5.2M. “This quarter was defined by strong execution that is driving momentum across our business,” said Ian ...

Stoke Therapeutics ( ($STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Analysts have given Stoke Therapeutics a total of 3 ratings, with the consensus rating being Buy. The average one-year price target is $29.0, indicating a potential 121.37% upside.

The U.S. Food and Drug Administration has already awarded zorevunersen (also known as STK-001) with breakthrough therapy designation for treating Dravet syndrome. Jefferies highlighted that investors ...

According to Jefferies, Phase I/II open-label data suggests zorevunersen can reduce seizures by month six of treatment and improve cognitive and behavioral measures by month nine, indicating ...

Recognized for its potential, zorevunersen has received FDA Breakthrough Therapy Designation, as well as orphan drug and rare pediatric disease designations.

Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study.

In August 2024, the FDA lifted a partial clinical hold, allowing the advancement of Zorevunersen (STK-001) into a Phase III registrational trial for children and adolescents with Dravet syndrome.